Hualan Biological Engineering, Inc. (002007.SZ) Latest Company News

Oct 27, 2026, 08:10 UTC
Hualan Biological Engineering reported revenue of 2.582 billion yuan for the first three quarters of 2026, down 23.58% year over year, and net profit attributable to shareholders of 431 million yuan, down 45.11%.
Source:
- finance.sina.cn
Oct 27, 2026, 08:10 UTC
Hualan Biological Engineering reported third-quarter 2026 revenue of 1.016 billion yuan, down 35.75% year over year, and net profit attributable to shareholders of 47.248 million yuan, down 82.41%.
Source:
- finance.sina.cn
Sep 23, 2026, 07:54 UTC
China's National Medical Products Administration accepted the marketing authorization application for Hualan Ankang Biopharmaceutical's trastuzumab for injection.
Source:
- finance.sina.cn
Sep 8, 2026, 15:53 UTC
Hualan Biological Engineering announced its interim dividend plan for the first half of 2026, proposing to distribute a cash dividend of 2 CNY (tax inclusive) per 10 shares to all shareholders, totaling approximately 365 million CNY.
Source:
- wap.eastmoney.com
Sep 7, 2026, 02:50 UTC
Hualan Biological Vaccine Co., Ltd. reduced its registered capital from 601.0275 million yuan to 565.028 million yuan, a decrease of about 6%, and changed its legal representative from An Kang to An Wenjue.
Source:
- finance.sina.cn
Aug 28, 2026, 08:19 UTC
Hualan Biological reported first-half revenue of 1.57 billion RMB and net profit of 383.4 million RMB.
Source:
- finance.sina.cn
Aug 10, 2026, 07:34 UTC
Hualan Biological's controlling subsidiary Hualan Vaccine is conducting research and development of a novel influenza virus mRNA vaccine.
Source:
- finance.sina.cn
Jul 21, 2026, 12:22 UTC
The first batch of influenza vaccines for the second half of 2026 has been approved for lot release and launched on July 21, 2026, with products from Sinovac and Hualan Vaccine among those included.
Source:
- finance.sina.cn
Jul 17, 2026, 08:44 UTC
Huaren Bio's deputy general manager Chen Zhengyue resigned for personal reasons and will remain in another role at the company.
Source:
- finance.sina.cn

002007.SZ

Hualan Biological Engineering reported revenue of 2.582 billion yuan for the first three quarters of 2026, down 23.58% year over year, and net profit attributable to shareholders of 431 million yuan, down 45.11%.

Hualan Biological Engineering reported third-quarter 2026 revenue of 1.016 billion yuan, down 35.75% year over year, and net profit attributable to shareholders of 47.248 million yuan, down 82.41%.

China's National Medical Products Administration accepted the marketing authorization application for Hualan Ankang Biopharmaceutical's trastuzumab for injection.

Hualan Biological Engineering announced its interim dividend plan for the first half of 2026, proposing to distribute a cash dividend of 2 CNY (tax inclusive) per 10 shares to all shareholders, totaling approximately 365 million CNY.

Hualan Biological Vaccine Co., Ltd. reduced its registered capital from 601.0275 million yuan to 565.028 million yuan, a decrease of about 6%, and changed its legal representative from An Kang to An Wenjue.

Hualan Biological reported first-half revenue of 1.57 billion RMB and net profit of 383.4 million RMB.

Hualan Biological's controlling subsidiary Hualan Vaccine is conducting research and development of a novel influenza virus mRNA vaccine.

The first batch of influenza vaccines for the second half of 2026 has been approved for lot release and launched on July 21, 2026, with products from Sinovac and Hualan Vaccine among those included.

Huaren Bio's deputy general manager Chen Zhengyue resigned for personal reasons and will remain in another role at the company.